ENALAPRIL/HYDROCHLOROTHIAZIDE SANDOZ 20 mg/12,5 mg, comprimé sécable Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

enalapril/hydrochlorothiazide sandoz 20 mg/12,5 mg, comprimé sécable

sandoz - maléate d'énalapril 20 mg; hydrochlorothiazide 12 - comprimé - 20 mg - pour un comprimé > maléate d'énalapril 20 mg > hydrochlorothiazide 12,5 mg - énalapril et diurétiques - code atc : c09ba02. - les comprimés d’enalapril/hydrochlorothiazide sandoz contiennent une association d'énalapril et d'hydrochlorothiazide et sont utilisés pour le traitement de l'hypertension artérielle quand l'énalapril utilisé seul se montre insuffisamment efficace.votre médecin peut également vous prescrire des comprimés d’enalapril/ hydrochlorothiazide sandoz à la place de comprimés séparés contenant les mêmes doses d'énalapril et d'hydrochlorothiazide.cette association à dose fixe ne convient pas pour le traitement initial.vous devez contacter votre médecin si vous ne vous sentez pas mieux ou si vous vous sentez moins bien.l'énalapril fait partie d'un groupe de médicaments appelés les « inhibiteurs de l'enzyme de conversion de l'angiotensine » (iec) et il diminue la pression artérielle en provoquant une dilatation des vaisseaux sanguins.l'hydrochlorothiazide fait partie d'un groupe de médicaments appelés les diurétiques et il diminue la pression artérielle en augmentant l'élimination d'urine.

ENALAPRIL/HYDROCHLOROTHIAZIDE MYLAN PHARMA 20 mg/12,5 mg, comprimé sécable Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

enalapril/hydrochlorothiazide mylan pharma 20 mg/12,5 mg, comprimé sécable

mylan sas - maléate d'énalapril 20 mg; hydrochlorothiazide 12 - comprimé - 20 mg - pour un comprimé > maléate d'énalapril 20 mg > hydrochlorothiazide 12,5 mg - classe pharmacothérapeutique: inhibiteurs de l'enzyme de conversion et diuretiques - classe pharmacothérapeutique inhibiteurs de l'enzyme de conversion et diurétiques – code atc : c09ba02enalapril/hydrochlorothiazide mylan pharma 20 mg/12,5 mg, comprimé sécable contient une association de maléate d’énalapril et d’hydrochlorothiazide. l'énalapril appartient à un groupe de médicaments appelés inhibiteurs de l'enzyme de conversion de l'angiotensine (iec), lesquels abaissent la pression artérielle en élargissant les vaisseaux sanguins. l'hydrochlorothiazide appartient à un groupe de médicaments appelés diurétiques lesquels abaissent la pression artérielle en augmentant l'excrétion urinaire.enalapril/hydrochlorothiazide mylan pharma 20 mg/12,5 mg, comprimé sécable est utilisé pour le traitement de l'hypertension en cas de contrôle insuffisant par traitement par énalapril seul.votre médecin peut également vous prescrire enalapril/hydrochlorothiazide mylan pharma à la place de comprimés individuels d'énalapril et d'hydrochlorothiazide au même dosage.cette association fixe de principes actifs n'est pas adaptée comme premier traitement de l'hypertension.

ENALAPRIL/HYDROCHLOROTHIAZIDE ARROW 20 mg/12,5 mg, comprimé sécable Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

enalapril/hydrochlorothiazide arrow 20 mg/12,5 mg, comprimé sécable

arrow generiques - maléate d'énalapril 20 mg; hydrochlorothiazide 12 - comprimé - 20 mg - pour un comprimé > maléate d'énalapril 20 mg > hydrochlorothiazide 12,5 mg - inhibiteurs de l'enzyme de conversion et diuretiques - classe pharmacothérapeutique : inhibiteurs de l'enzyme de conversion et diurétiques - code atc : c09ba02.ce médicament est un antihypertenseur contenant deux principes actifs, dont un diurétique, l’autre principe actif appartenant au groupe des inhibiteurs de l'enzyme de conversion.ce médicament est préconisé dans le traitement de l'hypertension artérielle, en cas de contrôle insuffisant sous un seul médicament (inhibiteur de l'enzyme de conversion).

ENALAPRIL/HYDROCHLOROTHIAZIDE BIOGARAN 20 mg/12,5 mg, comprimé sécable Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

enalapril/hydrochlorothiazide biogaran 20 mg/12,5 mg, comprimé sécable

biogaran - maléate d'énalapril 20 mg; hydrochlorothiazide 12 - comprimé - 20 mg - pour un comprimé > maléate d'énalapril 20 mg > hydrochlorothiazide 12,5 mg - inhibiteurs de l’enzyme de conversion et diurétiques - classe pharmacothérapeutique : inhibiteurs de l’enzyme de conversion et diurétiques ‑ code atc : c09ba02.ce médicament est un antihypertenseur contenant 2 principes actifs, dont un diurétique, l’autre principe actif appartenant au groupe des inhibiteurs de l’enzyme de conversion.ce médicament est préconisé dans le traitement de l’hypertension artérielle, en cas de contrôle insuffisant sous un seul médicament (inhibiteur de l’enzyme de conversion).

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE tablet USA - engelsk - NLM (National Library of Medicine)

enalapril maleate and hydrochlorothiazide tablet

rebel distributors corp - enalapril maleate (unii: 9o25354epj) (enalapril - unii:69pn84io1a), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - enalapril maleate 10 mg - when used in pregnancy during the second and third trimesters, ace inhibitors can cause injury and even death to the developing fetus. when pregnancy is detected, enalapril maleate/hydrochlorothiazide tablets should be discontinued as soon as possible. see warnings, pregnancy, enalapril maleate, fetal/neonatal morbidity and mortality. enalapril maleate/hydrochlorothiazide is indicated for the treatment of hypertension. these fixed dose combinations are not indicated for initial treatment (see dosage and administration ). in using enalapril maleate/hydrochlorothiazide, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk. (see warnings .) in considering use of enalapril maleate/hydrochlorothiazide, it should be noted that black patients receiving ace inhibitors h

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE tablet USA - engelsk - NLM (National Library of Medicine)

enalapril maleate and hydrochlorothiazide tablet

nucare pharmaceuticals,inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - enalapril maleate 10 mg - enalapril maleate and hydrochlorothiazide is indicated for the treatment of hypertension. this fixed dose combination is not indicated for initial treatment (see dosage and administration ). in using enalapril maleate and hydrochlorothiazide, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see warnings ). in considering use of enalapril maleate and hydrochlorothiazide, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see warnings, head and neck angioedema ). enalapril maleate and hydrochlorothiazide is contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of an

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE tablet USA - engelsk - NLM (National Library of Medicine)

enalapril maleate and hydrochlorothiazide tablet

dr. reddy's laboratories limited - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - enalapril maleate 5 mg - enalapril maleate and hydrochlorothiazide tablets are indicated for the treatment of hypertension. these fixed dose combinations are not indicated for initial treatment (see dosage and administration ). in using enalapril maleate and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see warnings ). in considering use of enalapril maleate and hydrochlorothiazide tablets, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see warnings, head and neck angioedema ). enalapril maleate and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angi

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE tablet USA - engelsk - NLM (National Library of Medicine)

enalapril maleate and hydrochlorothiazide tablet

mylan pharmaceuticals inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - enalapril maleate 5 mg - enalapril maleate and hydrochlorothiazide tablets are indicated for the treatment of hypertension. this fixed dose combination is not indicated for initial treatment (see dosage and administration). in using enalapril maleate and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see warnings). in considering use of enalapril maleate and hydrochlorothiazide tablets, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see warnings: head and neck angioedema). enalapril maleate and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE tablet USA - engelsk - NLM (National Library of Medicine)

enalapril maleate and hydrochlorothiazide tablet

taro pharmaceuticals u.s.a., inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - enalapril maleate 5 mg - enalapril maleate and hydrochlorothiazide is indicated for the treatment of hypertension. this fixed dose combination is not indicated for initial treatment (see dosage and administration ). in using enalapril maleate and hydrochlorothiazide, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see warnings ). in considering use of enalapril maleate and hydrochlorothiazide, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see warnings, head and neck angioedema ). enalapril maleate and hydrochlorothiazide is contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema. because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. enalapril maleate and hydrochlorothiazide is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer enalapril maleate and hydrochlorothiazide within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see warnings ). do not co-administer aliskiren with enalapril maleate and hydrochlorothiazide in patients with diabetes (see precautions, drug interactions ).

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE- enalapril maleate and hydrochlorothiazide tablet USA - engelsk - NLM (National Library of Medicine)

enalapril maleate and hydrochlorothiazide- enalapril maleate and hydrochlorothiazide tablet

cosette pharmaceuticals, inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - enalapril maleate 5 mg - enalapril maleate and hydrochlorothiazide tablets, usp are indicated for the treatment of hypertension. these fixed dose combinations are not indicated for initial treatment (see dosage and administration ). in using enalapril maleate and hydrochlorothiazide tablets, usp, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see warnings ). in considering use of enalapril maleate and hydrochlorothiazide tablets, usp, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see warnings , head and neck angioedema ). enalapril maleate and hydrochlorothiazide is contraindicated in patients who are hypersensitive to any component of this product and in patients with a history